(MedPage Today) — SAN FRANCISCO — Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from the phase III PREVAIL…
Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118297
Author :
Publish date : 2025-11-03 22:43:00
Copyright for syndicated content belongs to the linked Source.
